These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25712934)

  • 1. Pro: cardiovascular calcifications are clinically relevant.
    Bover J; Evenepoel P; Ureña-Torres P; Vervloet MG; Brandenburg V; Mazzaferro S; Covic A; Goldsmith D; Massy ZA; Cozzolino M;
    Nephrol Dial Transplant; 2015 Mar; 30(3):345-51. PubMed ID: 25712934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineral metabolism and cardiovascular disease in CKD.
    Fujii H; Joki N
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):53-63. PubMed ID: 28062938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?
    Cozzolino M; Ureña-Torres P; Vervloet MG; Brandenburg V; Bover J; Goldsmith D; Larsson TE; Massy ZA; Mazzaferro S;
    Nephrol Dial Transplant; 2014 Oct; 29(10):1815-20. PubMed ID: 24516228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular calcifications in chronic kidney disease: Potential therapeutic implications.
    Bover J; Ureña-Torres P; Górriz JL; Lloret MJ; da Silva I; Ruiz-García C; Chang P; Rodríguez M; Ballarín J
    Nefrologia; 2016; 36(6):597-608. PubMed ID: 27595517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].
    Iwashita Y; Iwashita Y; Ito T; Shigematsu T
    Clin Calcium; 2016 Feb; 26(2):259-67. PubMed ID: 26813506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jul; 17(10):1363-73. PubMed ID: 27156578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Con: vascular calcification is a surrogate marker, but not the cause of ongoing vascular disease, and it is not a treatment target in chronic kidney disease.
    Zoccali C; London G
    Nephrol Dial Transplant; 2015 Mar; 30(3):352-7. PubMed ID: 25712936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic procedures and rationale for specific therapies in chronic kidney disease-mineral and bone disorder.
    Bover J; Canal C; Marco H; Fernandez-Llama P; Bosch RJ; Ballarín J
    Contrib Nephrol; 2008; 161():222-233. PubMed ID: 18451681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)].
    Omata M; Fukagawa M; Kakuta T
    Clin Calcium; 2015 May; 25(5):645-53. PubMed ID: 25926567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.
    Brandenburg VM; D'Haese P; Deck A; Mekahli D; Meijers B; Neven E; Evenepoel P
    Pediatr Nephrol; 2016 Feb; 31(2):195-206. PubMed ID: 25735207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathogenesis and treatment of vascular calcification in CKD].
    Brancaccio D; Gallieni M; Pasho S; Fallabrino G; Olivi L; Volpi E; Ciceri P; Missaglia E; Ronga C; Brambilla C; Butti A; Rocca-Rey L; Chiarelli G; Cozzolino M
    G Ital Nefrol; 2009; 26 Suppl 45():S20-7. PubMed ID: 19382090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy for the altered mineral metabolism of chronic kidney disease: implications for vascular calcification.
    Saab G; Whaley-Connell AT; Khanna R; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Dec; 1(2):107-12. PubMed ID: 19124399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.
    Mehrotra R
    J Ren Nutr; 2006 Apr; 16(2):100-18. PubMed ID: 16567266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic perspectives for vascular and valvular calcifications in chronic kidney disease.
    Huish S; Sinha S
    Curr Opin Nephrol Hypertens; 2024 Jul; 33(4):391-397. PubMed ID: 38573243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis.
    Ruderman I; Holt SG; Hewitson TD; Smith ER; Toussaint ND
    Semin Dial; 2018 Sep; 31(5):487-499. PubMed ID: 29733462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of cardiovascular calcifications: Is it a useful tool for nephrologists?
    Bover J; Górriz JL; Ureña-Torres P; Lloret MJ; Ruiz-García C; daSilva I; Chang P; Rodríguez M; Ballarín J
    Nefrologia; 2016; 36(6):587-596. PubMed ID: 27575927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.
    Cozzolino M; Rizzo MA; Stucchi A; Cusi D; Gallieni M
    Ther Adv Chronic Dis; 2012 Mar; 3(2):59-68. PubMed ID: 23251769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.